The SMC’s mission is to improve the public understanding of science by ensuring that the news media has easy access to the very best experts and evidence when science hits the headlines.
Two papers published in JAMA Cardiology look at myocarditis following vaccination with mRNA COVID-19 vaccines, Moderna or Pfizer-BioNTech.
A research letter published in The Lancet looks at Oxford-AstraZeneca vaccine-induced neutralising antibody activity against different SARS-CoV-2 variants.
A case report published in the Annals of Internal Medicine looks at a single case of thrombocytopenia with thrombosis syndrome (TTS) after receiving the Moderna COVID-19 vaccine.
A study published in Nature suggests that the Pfizer-BioNTech COVID-19 vaccine induces persistent human germinal centre responses.
A preprint, an unpublished non-peer reviewed study, from the Com-COV trials, looks at the immune response to mixed dose scheduling of the Oxford-AstraZeneca and Pfizer-BioNTech COVID-19 vaccines.
A preprint, an unpublished non-peer reviewed study, looks at tolerability and immunogenicity after a late second dose or a third dose of the Oxford-AstraZeneca COVID-19 vaccine.
A few journalists have asked about MHRA yellow card reports relating to periods after the COVID-19 vaccine, as reported on in the Sunday Times, so here are some expert comments in case useful.
A study published in the New England Journal of Medicine (NEJM) looks at mRNA Covid-19 Vaccine Safety in Pregnancy.
CureVac have published a press release announcing the results of the second interim analysis of the international pivotal Phase 2b/3 trial of their COVID-19 vaccine candidate, CVnCoV.
A preprint, an unpublished non-peer reviewed study, from Public Health England (PHE), looks at effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant.
A press release from Novavax states that their COVID-19 vaccine candidate demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in the PREVENT-19 Phase 3 trial.
Expert reaction to study looking at the Oxford AstraZeneca COVID-19 vaccine and idiopathic thrombocytopenic purpura (ITP), a condition that affects the blood, as published in Nature Medicine*
A lab study from the UK has looked at blood neutralising antibody levels from people vaccinated with one or two doses of the Pfizer vaccine, against different variants of SARS-CoV-2 including the B.1.617.2 delta (Indian) variant, as published in the Lancet*
A preprint, an unpublished non-peer reviewed study, from researchers in Germany presents a theory for why vector-based COVID-19 vaccines, such as Oxford-AstraZeneca and Johnson & Johnson, may cause rare blood clots.
A study published in the New England Journal of Medicine (NEJM) looks at safety, immunogenicity, and efficacy results from the Pfizer-BioNtech COVID-19 vaccine trial in children aged 12 to 15.
The UK Science Media Centre has its roots in the influential House of Lords Science and Technology Select Committee third report on Science and Society, which sought to renew public trust in science after media frenzies on GM Crops and MMR. Established in 2002, it is an independent press office with a database of 3000 top quality scientists prepared to engage with journalists.
The Centre proactively makes the best scientists available to:
-Answer journalists questions on topical controversies
-Comment on breaking news and challenge misleading claims
- Assess new scientific findings, highlighting caveats and limitations
-Publicise new science in a measured and accurate way
The SMC’s philosophy is:
“The media will DO science better when scientists DO the media better.”
The UK Science Media Centre has its roots in the influential House of Lords Science and Technology Select Committee third report on Science and Society, which sought to renew public trust in science after media frenzies on GM Crops and MMR. Established in 2002, it is an independent press office with a database of 3000 top quality scientists prepared to engage with journalists.
The Centre proactively makes the best scientists available to:
-Answer journalists questions on topical controversies
-Comment on breaking news and challenge misleading claims
- Assess new scientific findings, highlighting caveats and limitations
-Publicise new science in a measured and accurate way
The SMC’s philosophy is:
“The media will DO science better when scientists DO the media better.”
